Lumida
/RPRX
⌘K
Royalty Pharma PLC

Royalty Pharma PLC

RPRX
$58.75USD-3.04%-1.84 today

MARKET CAP

33.8B

P/E (TTM)

30.8x

FWD P/E

DAY RANGE

$59 – $61

52W RANGE

$35
$64

AI Summary

Stalk
TrimMedium

After a decisive support failure in mid-September that signals sellers in control, RPRX remains in a Stage 4 decline. Price is currently pulling back into the broken support cluster and declining short-term EMAs, offering a deferred sell opportunity. The medium-term bias is bearish with no stabilization visible, while the long-term uptrend remains intact.

  • Portfolio receipts hit $773M (+6% YoY); total receipts grew 14%.
  • ROIC stood at 14.2% over trailing twelve months; Q2 operating cash flow $736M.
  • Negative book-to-price implies shares trading above intrinsic value.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$2.3B$2.2B$2.4B$2.3B$2.4B
YoY %+7.9%-2.3%+5.2%-3.9%+5.1%
P / Sales7.2x7.7x7.2x6.7x9.2x
EV / Sales9.7x10.2x9.7x9.8x13.1x
Gross Profit, Adj.$2.3B$2.2B$2.4B$2.3B$2.4B
YoY %+7.9%-2.3%+5.2%-3.9%+5.1%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit9.7x10.2x9.7x9.8x13.1x
EBITDA, Adj.$1.9B$1.8B$1.5B$1.3B$1.6B
YoY %-0.4%-4.2%-18.3%-13.4%+20.7%
Margin %83.3%81.7%63.4%57.1%65.6%
EV / EBITDA11.7x12.5x15.3x17.1x19.9x
EBIT$1.4B$307.1M$1.5B$1.3B$1.6B
YoY %-10.3%-78.5%+385.9%-13.4%+20.7%
Margin %62.5%13.7%63.4%57.1%65.6%
EV / EBIT15.6x74.4x15.3x17.1x19.9x
Net Income$619.7M$42.8M$1.1B$859.0M$770.9M
YoY %+25.1%-93.1%+2549.5%-24.3%-10.2%
Net Margin27.1%1.9%48.2%37.9%32.4%
EPS (GAAP)$1.49$0.10$2.53$1.91$1.78
YoY %+12.9%-93.3%+2430.0%-24.5%-6.8%